Groupama Asset Managment Sells 9,542 Shares of Johnson & Johnson (NYSE:JNJ)

Groupama Asset Managment cut its holdings in Johnson & Johnson (NYSE:JNJ) by 18.6% during the 4th quarter, Holdings Channel reports. The firm owned 41,892 shares of the company’s stock after selling 9,542 shares during the period. Groupama Asset Managment’s holdings in Johnson & Johnson were worth $6,005,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. OV Management LLC boosted its holdings in Johnson & Johnson by 8.7% in the fourth quarter. OV Management LLC now owns 10,572 shares of the company’s stock valued at $1,529,000 after acquiring an additional 843 shares in the last quarter. May Hill Capital LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth about $315,000. Invenio Wealth Partners LLC increased its position in shares of Johnson & Johnson by 3.7% during the fourth quarter. Invenio Wealth Partners LLC now owns 3,404 shares of the company’s stock valued at $492,000 after buying an additional 120 shares during the period. Lokken Investment Group LLC raised its stake in Johnson & Johnson by 1.7% in the fourth quarter. Lokken Investment Group LLC now owns 15,199 shares of the company’s stock worth $2,198,000 after buying an additional 247 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Johnson & Johnson by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company’s stock worth $8,321,881,000 after buying an additional 1,561,036 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $153.25 on Wednesday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The business’s fifty day simple moving average is $159.16 and its two-hundred day simple moving average is $155.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a market cap of $369.30 billion, a price-to-earnings ratio of 23.04, a P/E/G ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the company earned $2.29 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.24%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Analyst Ratings Changes

JNJ has been the subject of several research reports. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 10th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Stifel Nicolaus lowered their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Finally, Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $171.33.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.